Ecopipam

Research use only, not for human use.

Ecopipam (UNII-0X748O646K) is a potent, selective, and orally active antagonist of dopamine D1/D5 receptors, with Kis of 1.2 nM and 2.0 nM, respectively.

Ecopipam (SCH 39166) is a potent, selective and orally active antagonist of dopamine D1/D5 receptor, with Kis of 1.2 nM and 2.0 nM, respectively. Ecopipam shows more than 40-flod selectivity over D2, D4, 5-HT, and α2a receptor (Ki=0.98, 5.52, 0.08, and 0.73 μM, respectively). Ecopipam can be used for the research of schizophrenia and obesity.

——

Animal Model:Male young adult Long-Evans rats injected with Nicotine Dosage:0.003, 0.01, 0.03, 0.1, 0.3 mg/kg Administration:A single s.c. 20 min before Nicotine (0.1 mg/kg)Result:Dose-dependently reduced pressing on both active and inactive levers.

——

GPCR/G Protein

Dopamine Receptor

Dopamine Receptor

——

——

112108-01-7

313.82

C19H20ClNO

>98% (HPLC)

——

CN1[C@@]2([C@@](C=3C(=CC(Cl)=C(O)C3)CC1)(C=4C(CC2)=CC=CC4)[H])[H]

——

(-20℃)

With Ice Pack

≥ 2 years